Specialty Pharmacy

New hepatitis C drugs moved the dream of a cure into a reality that gives patients a new chance at life.

Researchers discuss mechanism for overcoming resistance to drugs that target BRAF protein.

Oregon allows pharmacists to be reimbursed for performing clinical pharmacy services.

Pharmacists can reassure patients taking pre-exposure prophylaxis that the human immunodeficiency virus prevention treatment will not increase their risk for depression.

Increasing immune cell infiltration into tumors induces the immune system to block tumor growth.

Ron Lanton III, Esq, president of True North Political Solutions, LLC, discusses how the specialty pharmacy landscape will evolve in the coming years.

Sandoz has begun shipping glatiramer acetate (Glatopa), the first FDA-approved generic competitor to Teva's Copaxone multiple sclerosis (MS) drug.

Hyperlipidemia found to alter immune response.

Top stories of the week on Specialty Pharmacy Times from June 15 to June 19.

Allegations include conspiracy to commit health care fraud, violations of the anti-kickback statutes, money laundering, and aggravated identity theft.

Patients achieve drug-free remission with less expensive biologic drugs during first 2 years of treatment.

Lipid from avocados targets leukemia stem cells.

Respiratory diseases afflict a large portion of the global population and result in significant disease burden.

Modifying small white blood cells shows promise in treating immune disorders.

Marc O'Connor, Chief Operating Officer of Curant Health, discusses how to evaluate the short term cost of treatment with new hepatitis C drugs versus the long term cost of care.

Young adults reported having trouble navigating HealthCare.gov for a health insurance plan during the first Affordable Care Act (ACA) open enrollment period.

Necitumumab added to chemotherapy increases survival to nearly a year.

Physical aspects and quality of life issues improve with treatment.

The total cost of health must be considered in light of a potential cure.

Many patients experience distress from concerns over treatment and disease progression.

Heather Bonome, PharmD, director of Pharmacy Segment at URAC, discusses how accreditation programs can enhance health care overall.

The FDA is currently reviewing Teva's reslizumab treatment for adult and adolescent asthmatics with symptoms inadequately controlled by inhaled corticosteroid (ICS) regimens.

New cases have increased by nearly 50% over last 30 years.

Either patient group in need of more intensive treatment to reduce surgery risk.

Duration of sleep and snoring may play a role in survival outcomes.

Top stories of the week on Specialty Pharmacy Times from June 8-12.

Agency notes that expedited approvals do not compromise quality standards.

Study finds greater unmet needs for basic services compared with male patients.